Navigation Links
Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
Date:11/16/2011

CHICAGO Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions.

"Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel," according to background information in the article. Variability in the pharmacodynamic response to clopidogrel is well recognized, and patients with higher platelet reactivity while receiving clopidogrel are at increased risk of adverse cardiovascular events. " data are needed to offer guidance as to what might constitute optimal treatment strategies in patients with loss-of-function CYP2C19 alleles [an alternative form of a gene]."

Jessica L. Mega, M.D., M.P.H., and Marc S. Sabatine, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues conducted a multicenter, randomized trial to test whether maintenance doses of up to 300 mg daily of clopidogrel can improve platelet reactivity in the setting of loss-of-function CYP2C19 genotypes, particularly among heterozygotes (a person possessing one copy of a variant gene), who constitute approximately 25 percent to 45 percent of the population, depending on racial background. The trial (ELEVATE-TIMI 56) enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.

Patients received maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were randomized to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes [having two copies of the variant gene]) were randomized to receive 75, 150, 225, and 300 mg daily. Two methods were used to measure platelet function. The average age of the patients was 60 years, 75 percent were male, 57 percent had a history of heart attack, and 97 percent had a history of percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

Among the main findings of the researchers was that higher maintenance doses of clopidogrel in patients carrying a CYP2C19*2 allele significantly reduced platelet reactivity. Also, daily maintenance doses of 225 mg of clopidogrel or greater in CYP2C19*2 heterozygotes improved platelet reactivity levels that were at least equivalent to what is achieved with 75 mg daily of clopidogrel in noncarrier patients with cardiovascular disease. When evaluating the CYP2C19*2 homozygotes, the researchers saw a trend toward less platelet reactivity with higher maintenance doses of clopidogrel; however, even with 300 mg daily of clopidogrel, these individuals were unlikely to achieve optimal degrees of platelet inhibition.

"These data help define how patients with different CYP2C19 genotypes respond to clopidogrel maintenance dosing strategies and provides useful information to guide further clinical studies," the authors conclude.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
quellenberg@partners.org
617-534-2208
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. NYUCN receives $994,000 HRSA grant to research increasing nursing faculty diversity
2. Study finds liver cancer increasing in low risk countries, decreasing in high risk countries
3. Local efforts can stem the increasing unnecessary cesarean sections
4. Vascular disease management increasingly important
5. Researchers find increasing the number of family physicians reduces hospital readmissions
6. Success of First World Congress of Pediatric Urology underscores increasing importance of specialty
7. UNC study finds oral tongue cancer increasing in young, white females
8. Income inequalities are increasing the occurence of depression during financial crisis
9. Increasingly, Other Ailments Prove Fatal for People With COPD
10. Hospice care increasing for nursing home patients with dementia
11. Influenza virus strains show increasing drug resistance and ability to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association ... marketing programs at the annual Building Better Radiology Marketing Programs conference, held ... in Fort Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive ... was named a 2017 Top Patient Rated Henderson Dentist by Find Local ... recognizes local physicians and dentists who have earned high ratings and superior patient reviews ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology: